Abstract:Ras proteins are small GTPases, cycling between inactive GDP-bound and active GTP-bound states. Through these switches they regulate signaling that controls cell growth and proliferation. Activating Ras mutations are associated with approximately 30% of human cancers, which are frequently resistant to standard therapies. Over the past few years, structural biology and in silico drug design, coupled with improved screening technology, led to a handful of promising inhibitors, raising the possibility of drugging Ras proteins. At the same time, the invariable emergence of drug resistance argues for the critical importance of additionally honing in on signaling pathways which are likely to be involved. Here we overview current advances in Ras structural knowledge, including the conformational dynamic of full-length Ras in solution and at the membrane, therapeutic inhibition of Ras activity by targeting its active site, allosteric sites, and Ras-effector protein-protein interfaces, Ras dimers, the K-Ras4B/calmodulin/PI3K alpha trimer, and targeting Ras with siRNA. To mitigate drug resistance, we propose signaling pathways that can be co-targeted along with Ras and explain why. These include pathways leading to the expression (or activation) of YAP1 and c-Myc. We postulate that these and Ras signaling pathways, MAPK/ERK and PI3K/Akt/mTOR, act independently and in corresponding ways in cell cycle control. The structural data are instrumental in the discovery and development of Ras inhibitors for treating RAS-driven cancers. Together with the signaling blueprints through which drug resistance can evolve, this review provides a comprehensive and innovative master plan for tackling mutant Ras proteins.

Synthesis of Ras Proteins and Their Application in Biofunctional Studies

Progresses In Synthesis Of Lipoproteins

Post-translational modification of KRAS: potential targets for cancer therapy

Targeting RAS mutants in malignancies: successes, failures, and reasons for hope

Targeting RAS Phosphorylation in Cancer Therapy: Mechanisms and Modulators

Progress in RAS-targeted Therapeutic Strategies: from Small Molecule Inhibitors to Proteolysis Targeting Chimeras.

Epigenetic Silencing of a Ca2+-regulated Ras GTPase-activating Protein RASAL Defines a New Mechanism of Ras Activation in Human Cancers

RAS‐targeted cancer therapy: Advances in drugging specific mutations

Drugging Ras Gtpase: A Comprehensive Mechanistic And Signaling Structural View

Control of the signaling of RAS proteins by modulating their palmitoylation

The role of protein post-translational modifications in prostate cancer

Protein post-translational modifications in the regulation of cancer hallmarks

Drugging Ras GTPase: a Comprehensive Mechanistic and Signaling Structural View.

An overview of recent advancements in small molecules suppression of oncogenic signaling of K-RAS: an updated review

design of Ras isoform selective binders

Development and safety of investigational and approved drugs targeting the RAS function regulation in RAS mutant cancers

A Proteomic Approach Identifies Isoform-Specific and Nucleotide-Dependent RAS Interactions

Small molecule inhibitors of RAS proteins with oncogenic mutations

Ras-GTP dimers activate the Mitogen-Activated Protein Kinase (MAPK) pathway

Inhibitors of Ras–SOS Interactions

Simultaneous Covalent Modification of K-Ras(G12D) and K-Ras(G12C) with Tunable Oxirane Electrophiles